Postmenopausal Female Hormone Use and Estrogen Receptor-Positive and -Negative Breast Cancer in African American Women

Lynn Rosenberg; Traci N Bethea; Emma Viscidi; Chi-Chen Hong; Melissa A Troester; Elisa V Bandera; Christopher A Haiman; Laurence N Kolonel; Andrew F Olshan; Christine B Ambrosone; Julie R Palmer

doi:10.1093/jnci/djv361

Back

Postmenopausal Female Hormone Use and Estrogen Receptor-Positive and -Negative Breast Cancer in African American Women

Journal article

Open access

Postmenopausal Female Hormone Use and Estrogen Receptor-Positive and -Negative Breast Cancer in African American Women

Lynn Rosenberg, Traci N Bethea, Emma Viscidi, Chi-Chen Hong, Melissa A Troester, Elisa V Bandera, Christopher A Haiman, Laurence N Kolonel, Andrew F Olshan, Christine B Ambrosone, …

JNCI : Journal of the National Cancer Institute, Vol.108(4), p.djv361

04/2016

DOI: https://doi.org/10.1093/jnci/djv361

PMCID: PMC4857155

PMID: 26613937

Abstract

African Americans - statistics & numerical data

Aged

Breast Neoplasms - chemically induced

Breast Neoplasms - chemistry

Breast Neoplasms - epidemiology

Estrogen Replacement Therapy - adverse effects

Estrogen Replacement Therapy - methods

Estrogens - administration & dosage

Female

Humans

Logistic Models

Middle Aged

Odds Ratio

Postmenopause

Progestins - administration & dosage

Receptors, Estrogen - analysis

Retrospective Studies

Risk Factors

United States - epidemiology

Use of estrogen with progestin (combination therapy) is associated with increased incidence of estrogen receptor-positive (ER+) breast cancer in observational studies and randomized trials among postmenopausal white women. Whether this is also the case among African American women is not established. Using data from the AMBER consortium collected from 1993 to 2013, we assessed use of estrogen alone and of combination therapy in relation to ER+ and ER-negative (ER-) breast cancer risk in postmenopausal African American women, based on 1132 ER+ case patients, 512 ER- case patients, and 6693 control patients. Odds ratios (ORs) and confidence intervals (CIs) were estimated using multinomial logistic regression with control for breast cancer risk factors. Forty-seven percent of control patients had used estrogen alone, combination therapy, or both. The odds ratio for ER+ breast cancer associated with combination use, relative to never use of either estrogen alone or combination therapy, was 1.50 (95% CI = 1.25 to 1.79). The increase was greater for recent (OR = 1.55, 95% CI = 1.21 to 1.99) and long-term use (OR = 1.75, 95% CI = 1.13 to 2.73) and among nonobese women (OR = 1.91, 95% CI = 1.29 to 2.83). Breast cancer risk was increased regardless of the interval between onset of menopause and initiation of combination use (OR = 1.43, 95% CI = 1.11 to 1.85, for <5 year interval; OR = 1.78, 95% CI = 1.34 to 2.37, for ≥5 year interval). Combination use was not associated with risk of ER- breast cancer, and use of estrogen alone was not associated with risk of either ER+ or ER- breast cancer. Use of estrogen with progestin increases risk of ER+ breast cancer in African American women. A decrease in use would be expected to reduce the number of ER+ cancers.

Files and links (1)

url

https://doi.org/10.1093/jnci/djv361View

Version of Record (VoR) Open

Metrics

13 Record Views

10 Times Cited - Web of Science

See more details

Details

Title: Postmenopausal Female Hormone Use and Estrogen Receptor-Positive and -Negative Breast Cancer in African American Women
Creators: Lynn Rosenberg - Slone Epidemiology Center at Boston University, Boston, MA (LR, TNB, EV, JRP); Roswell Park Cancer Institute, Buffalo, NY (CCH, CBA); University of North Carolina Lineberger Cancer Center, Chapel Hill, NC (MAT, AFO); Rutgers Cancer Institute of New Jersey, New Brunswick, NJ (EVB); Department of Preventive Medicine and Norris Comprehensive Cancer Cencer, University of Southern California Keck School of Medicine, Los Angeles, CA (CAH); Department of Public Health Sciences, University of Hawaii School of Medicine, Honolulu, HI (LNK). lrosenbe@bu.edu
Traci N Bethea - Slone Epidemiology Center at Boston University, Boston, MA (LR, TNB, EV, JRP); Roswell Park Cancer Institute, Buffalo, NY (CCH, CBA); University of North Carolina Lineberger Cancer Center, Chapel Hill, NC (MAT, AFO); Rutgers Cancer Institute of New Jersey, New Brunswick, NJ (EVB); Department of Preventive Medicine and Norris Comprehensive Cancer Cencer, University of Southern California Keck School of Medicine, Los Angeles, CA (CAH); Department of Public Health Sciences, University of Hawaii School of Medicine, Honolulu, HI (LNK)
Emma Viscidi - Slone Epidemiology Center at Boston University, Boston, MA (LR, TNB, EV, JRP); Roswell Park Cancer Institute, Buffalo, NY (CCH, CBA); University of North Carolina Lineberger Cancer Center, Chapel Hill, NC (MAT, AFO); Rutgers Cancer Institute of New Jersey, New Brunswick, NJ (EVB); Department of Preventive Medicine and Norris Comprehensive Cancer Cencer, University of Southern California Keck School of Medicine, Los Angeles, CA (CAH); Department of Public Health Sciences, University of Hawaii School of Medicine, Honolulu, HI (LNK)
Chi-Chen Hong - Slone Epidemiology Center at Boston University, Boston, MA (LR, TNB, EV, JRP); Roswell Park Cancer Institute, Buffalo, NY (CCH, CBA); University of North Carolina Lineberger Cancer Center, Chapel Hill, NC (MAT, AFO); Rutgers Cancer Institute of New Jersey, New Brunswick, NJ (EVB); Department of Preventive Medicine and Norris Comprehensive Cancer Cencer, University of Southern California Keck School of Medicine, Los Angeles, CA (CAH); Department of Public Health Sciences, University of Hawaii School of Medicine, Honolulu, HI (LNK)
Melissa A Troester - Slone Epidemiology Center at Boston University, Boston, MA (LR, TNB, EV, JRP); Roswell Park Cancer Institute, Buffalo, NY (CCH, CBA); University of North Carolina Lineberger Cancer Center, Chapel Hill, NC (MAT, AFO); Rutgers Cancer Institute of New Jersey, New Brunswick, NJ (EVB); Department of Preventive Medicine and Norris Comprehensive Cancer Cencer, University of Southern California Keck School of Medicine, Los Angeles, CA (CAH); Department of Public Health Sciences, University of Hawaii School of Medicine, Honolulu, HI (LNK)
Elisa V Bandera - Slone Epidemiology Center at Boston University, Boston, MA (LR, TNB, EV, JRP); Roswell Park Cancer Institute, Buffalo, NY (CCH, CBA); University of North Carolina Lineberger Cancer Center, Chapel Hill, NC (MAT, AFO); Rutgers Cancer Institute of New Jersey, New Brunswick, NJ (EVB); Department of Preventive Medicine and Norris Comprehensive Cancer Cencer, University of Southern California Keck School of Medicine, Los Angeles, CA (CAH); Department of Public Health Sciences, University of Hawaii School of Medicine, Honolulu, HI (LNK)
Christopher A Haiman - Slone Epidemiology Center at Boston University, Boston, MA (LR, TNB, EV, JRP); Roswell Park Cancer Institute, Buffalo, NY (CCH, CBA); University of North Carolina Lineberger Cancer Center, Chapel Hill, NC (MAT, AFO); Rutgers Cancer Institute of New Jersey, New Brunswick, NJ (EVB); Department of Preventive Medicine and Norris Comprehensive Cancer Cencer, University of Southern California Keck School of Medicine, Los Angeles, CA (CAH); Department of Public Health Sciences, University of Hawaii School of Medicine, Honolulu, HI (LNK)
Laurence N Kolonel - Slone Epidemiology Center at Boston University, Boston, MA (LR, TNB, EV, JRP); Roswell Park Cancer Institute, Buffalo, NY (CCH, CBA); University of North Carolina Lineberger Cancer Center, Chapel Hill, NC (MAT, AFO); Rutgers Cancer Institute of New Jersey, New Brunswick, NJ (EVB); Department of Preventive Medicine and Norris Comprehensive Cancer Cencer, University of Southern California Keck School of Medicine, Los Angeles, CA (CAH); Department of Public Health Sciences, University of Hawaii School of Medicine, Honolulu, HI (LNK)
Andrew F Olshan - Slone Epidemiology Center at Boston University, Boston, MA (LR, TNB, EV, JRP); Roswell Park Cancer Institute, Buffalo, NY (CCH, CBA); University of North Carolina Lineberger Cancer Center, Chapel Hill, NC (MAT, AFO); Rutgers Cancer Institute of New Jersey, New Brunswick, NJ (EVB); Department of Preventive Medicine and Norris Comprehensive Cancer Cencer, University of Southern California Keck School of Medicine, Los Angeles, CA (CAH); Department of Public Health Sciences, University of Hawaii School of Medicine, Honolulu, HI (LNK)
Christine B Ambrosone - Slone Epidemiology Center at Boston University, Boston, MA (LR, TNB, EV, JRP); Roswell Park Cancer Institute, Buffalo, NY (CCH, CBA); University of North Carolina Lineberger Cancer Center, Chapel Hill, NC (MAT, AFO); Rutgers Cancer Institute of New Jersey, New Brunswick, NJ (EVB); Department of Preventive Medicine and Norris Comprehensive Cancer Cencer, University of Southern California Keck School of Medicine, Los Angeles, CA (CAH); Department of Public Health Sciences, University of Hawaii School of Medicine, Honolulu, HI (LNK)
Julie R Palmer - Slone Epidemiology Center at Boston University, Boston, MA (LR, TNB, EV, JRP); Roswell Park Cancer Institute, Buffalo, NY (CCH, CBA); University of North Carolina Lineberger Cancer Center, Chapel Hill, NC (MAT, AFO); Rutgers Cancer Institute of New Jersey, New Brunswick, NJ (EVB); Department of Preventive Medicine and Norris Comprehensive Cancer Cencer, University of Southern California Keck School of Medicine, Los Angeles, CA (CAH); Department of Public Health Sciences, University of Hawaii School of Medicine, Honolulu, HI (LNK)
Publication Details: JNCI : Journal of the National Cancer Institute, Vol.108(4), p.djv361
Date published: 04/2016
Grant note: P50 CA58223 / NCI NIH HHS U01 ESO19472 / PHS HHS R01 CA058420 / NCI NIH HHS P2C HD050924 / NICHD NIH HHS R01 CA54281 / NCI NIH HHS UM1 CA164973 / NCI NIH HHS P30 CA016086 / NCI NIH HHS UM1 CA164974 / NCI NIH HHS P50 CA058223 / NCI NIH HHS R01 CA100598 / NCI NIH HHS P01 CA151135 / NCI NIH HHS
Academic Unit: Cancer Epidemiology and Health Outcomes
Language: English
Resource Type: Journal article
Identifiers: 991031664324204646